Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:759-764

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.
Right arrow Articles by Simon, D. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.
Right arrow Articles by Simon, D. I.
Related Collections
Right arrow Oxidant stress
Right arrow Other Vascular biology
Right arrow Apoptosis
Right arrow Cell biology/structural biology
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:759.)
© 2001 American Heart Association, Inc.


Vascular Biology

Photodynamic Therapy With Motexafin Lutetium Induces Redox-Sensitive Apoptosis of Vascular Cells

Zhiping Chen; Kathryn W. Woodburn; Can Shi; Daniel C. Adelman; Campbell Rogers; Daniel I. Simon

From the Cardiovascular Division (Z.C., C.S., C.R., D.I.S.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; Harvard-M.I.T. Division of Health Sciences and Technology (C.R.), Massachusetts Institute of Technology, Cambridge, Mass; and Pharmacyclics, Inc (K.W.W., D.C.A.), Sunnyvale, Calif.

Correspondence to Daniel I. Simon, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Tower 3, Boston, MA 02115. E-mail dsimon{at}rics.bwh.harvard.edu

Abstract—Motexafin lutetium is a photosensitizer that accumulates in atherosclerotic plaque and, after activation by far-red light, produces cytotoxic singlet oxygen. The combination of photosensitizer and illumination, known as photodynamic therapy (PDT), has been shown to reduce atheroma formation in animal models and is under clinical investigation. However, the effects of PDT with motexafin lutetium on isolated vascular cells are unknown. This study was designed to characterize the effects of PDT on vascular cell viability and to define the cell-death pathway for this agent. Fluorescence microscopy of RAW macrophages and human vascular smooth muscle cells revealed time-dependent uptake of motexafin lutetium. Illumination of motexafin lutetium–loaded cells with 732-nm light (2 J/cm2) impaired cellular viability and growth (IC50 5 to 20 µmol/L). Depletion of intracellular glutathione potentiated (P=0.035) and the addition of antioxidant N-acetylcysteine attenuated (P=0.002) cell death, suggesting that the intracellular redox state influences motexafin lutetium action. PDT was associated with the loss of mitochondrial membrane potential, mitochondrial release of cytochrome c, and caspase activation. PDT promoted phosphatidylserine externalization and induced apoptotic DNA fragmentation, with the number of apoptotic cells increasing from 7±2% to 34±3% of total cells. Reducing plaque cellularity by the induction of apoptosis may be one mechanism by which PDT reduces plaque burden, possibly modulates plaque vulnerability, and inhibits restenosis in vivo.


Key Words: apoptosis • photodynamic therapy • vascular cells • reactive oxygen species • atherosclerosis




This article has been cited by other articles:


Home page
HeartHome page
R Waksman, I M Leitch, J Roessler, H Yazdi, R Seabron, F Tio, R W Scott, R I Grove, S Rychnovsky, B Robinson, et al.
Intracoronary photodynamic therapy reduces neointimal growth without suppressing re-endothelialisation in a porcine model
Heart, August 1, 2006; 92(8): 1138 - 1144.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. J. Kereiakes, A. M. Szyniszewski, D. Wahr, H. C. Herrmann, D. I. Simon, C. Rogers, P. Kramer, W. Shear, A. C. Yeung, K. A. Shunk, et al.
Phase I Drug and Light Dose-Escalation Trial of Motexafin Lutetium and Far Red Light Activation (Phototherapy) in Subjects With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention and Stent Deployment: Procedural and Long-Term Results
Circulation, September 16, 2003; 108(11): 1310 - 1315.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. H. Shuhaiber, A. N. Evans, M. G. Massad, and A. S. Geha
Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery
Eur. J. Cardiothorac. Surg., September 1, 2002; 22(3): 387 - 396.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
C. A Thompson and S. N Oesterle
Biointerventional cardiology: the future interface of interventional cardiovascular medicine and bioengineering
Vascular Medicine, May 1, 2002; 7(2): 135 - 140.
[Abstract] [PDF]